Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Has Average Price Target of $23.00

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $23.00.

A number of equities research analysts recently commented on AMRX shares. Zacks Research upgraded shares of Amneal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, October 26th. UBS Group reissued a “buy” rating on shares of Amneal Pharmaceuticals in a report on Thursday, October 1st. JPMorgan Chase & Co. boosted their price objective on shares of Amneal Pharmaceuticals from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, November 4th. Leerink Partners upped their price objective on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. Finally, Oppenheimer started coverage on shares of Amneal Pharmaceuticals in a report on Wednesday, September 23rd. They set an “outperform” rating and a $27.00 target price for the company.

Get Our Latest Stock Analysis on Amneal Pharmaceuticals

Amneal Pharmaceuticals Trading Down 1.5%

AMRX stock traded down $0.32 during midday trading on Friday, hitting $21.38. The company had a trading volume of 1,717,832 shares, compared to its average volume of 4,133,451. The stock has a market cap of $6.83 billion, a price-to-earnings ratio of 50.90, a PEG ratio of 2.47 and a beta of 1.24. Amneal Pharmaceuticals has a 52 week low of $11.39 and a 52 week high of $22.07. The company has a current ratio of 1.87, a quick ratio of 1.24 and a debt-to-equity ratio of 5.61. The stock’s 50 day moving average price is $19.71 and its 200 day moving average price is $16.11.

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.03. Amneal Pharmaceuticals had a net margin of 4.17% and a return on equity of 283.50%. The firm had revenue of $862.68 million for the quarter. As a group, equities research analysts expect that Amneal Pharmaceuticals will post 0.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Public Employees Retirement System of Ohio bought a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth approximately $29,000. Fortitude Family Office LLC lifted its stake in Amneal Pharmaceuticals by 100.9% in the third quarter. Fortitude Family Office LLC now owns 1,607 shares of the company’s stock worth $32,000 after acquiring an additional 807 shares during the period. GAMMA Investing LLC lifted its stake in Amneal Pharmaceuticals by 54.9% in the third quarter. GAMMA Investing LLC now owns 1,605 shares of the company’s stock worth $32,000 after acquiring an additional 569 shares during the period. Sterling Capital Management LLC lifted its stake in Amneal Pharmaceuticals by 30.3% in the third quarter. Sterling Capital Management LLC now owns 3,549 shares of the company’s stock worth $71,000 after acquiring an additional 825 shares during the period. Finally, KBC Group NV bought a new stake in Amneal Pharmaceuticals in the first quarter valued at $80,000. Institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

(Get Free Report)

Amneal Pharmaceuticals is a U.S.-based pharmaceutical company that develops, manufactures and markets generic and specialty medicines. Its products include a broad range of generic drugs, including complex formulations and injectable medicines, as well as branded therapies in areas such as neurology and endocrinology. The company also operates AvKARE, which distributes pharmaceuticals and medical products to government, institutional and commercial customers. Amneal serves customers in the United States and in international markets.

See Also

Analyst Recommendations for Amneal Pharmaceuticals (NASDAQ:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.